PD-1 targeting immunotherapy MK-3475 has high, long-lasting activity against metastatic melanoma

Share :
Published: 2 Jun 2014
Views: 3105
Dr Antoni Ribas – UCLA Jonsson Comprehensive Cancer Center, Los Angeles, US

At a press conference at ASCO 2014, Dr Ribas talks about his work which looks at the efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

Read the article for more.